Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.

If, as monthly START-UP contributor Michael Lytton (general partner at Oxford Bioscience Partners) wrote in a recent "Nothing Ventured" column, "the first ingredient of a successful tool company deal is to invest as little capital as possible" (see "The Value in Tool Companies," START-UP, March 2004 Also see "The Value in Tool Companies" - Scrip, 1 March, 2004.), what then to make of the hefty $27 million raised by Helicos BioSciences Corp. , a developer of high-throughput sequencing systems, in its initial venture round in February? [See Deal] Only one other privately held tool company has raised more than $20 million since last September—ParAllele BioScience Inc. , also a developer of high-throughput genomics tools, in its B round last fall. [See Deal](See "ParAllele BioScience Inc.," START-UP, October 2003 Also see "ParAllele BioScience Inc." - Scrip, 1 October, 2003..)

Along with the usual arguments--the pedigree of its founders and advisers (which in Helicos' case include Leroy Hood, PhD, the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.